Frankfurt - Delayed Quote • EUR Swedish Orphan Biovitrum AB (publ) (B6E.F) Follow Add holdings 27.84 -0.74 (-2.59%) At close: May 23 at 9:22:56 AM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for B6E.F 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: B6E.F View More All News Press Releases SEC Filings Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Highlights: Strong Haematology Growth ... Sobi publishes Q1 2025 report: Portfolio continues to deliver Sobi presents clinical data at WFH 2025 Comprehensive Care Summit Invitation: Sobi's Q1 report Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) Sobi publishes Annual and sustainability report for 2024 Sobi announces a new research collaboration on the development of Gamifant® (emapalumab) in sepsis, which is to be presented at the ISICEM congress US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg) EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN Sobi publishes Q4 2024 report: A solid ending to a strong year